Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients
- 820 Downloads
Radioactive iodine therapy is administered to patients with differentiated thyroid cancer (DTC) for eradication of thyroid remnant after total thyroidectomy or, in patients with metastatic disease, for curative or palliative treatment. In past years, thyroid remnant ablation was indicated in almost every patient with a diagnosis of DTC. Nowadays, careful revision of patients’ outcome has introduced the concept of risk-based selection of patients candidate to thyroid remnant ablation. The present review aims to underline the indications for thyroid remnant ablation and to address methodologies to be employed.
KeywordsRadioiodine Thyroid ablation Thyroid cancer Thyroglobulin rhTSH
This work was supported in part by Grants from: Ministero Italiano dell’Università e Ricerca (MIUR) (Grant Number 2012Z3F7HE).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by the author.
Formal consent is not required.
- 3.Haugen BR, Alexander EK, Bible KC et al (2016) American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1):1–133CrossRefPubMedGoogle Scholar
- 19.Elisei R, Viola D, Torregrossa L et al (2012) The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 97:4390–4398CrossRefPubMedGoogle Scholar
- 27.Webb RC, Howard RS, Stojadinovic A et al (2012) The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab 97:2754–2763CrossRefPubMedGoogle Scholar
- 29.Piccardo A, Arecco F, Morbelli S et al (2010) Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer. J Endocrinol Invest 33:83–87CrossRefPubMedGoogle Scholar
- 31.Heemstra KA, Liu YY, Stokkel M et al (2007) Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol 66:58–64Google Scholar
- 34.Nascimento C, Borget I, Al Ghuzlan A et al (2011) Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer 18:29–40Google Scholar
- 46.Pacini F, Ladenson PW, Schlumberger M et al (2006) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926–932CrossRefPubMedGoogle Scholar
- 51.Molinaro E, Giani C, Agate L et al (2013) Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity 131I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. J Clin Endocrinol Metab 98:2693–2700CrossRefPubMedGoogle Scholar
- 61.Pilli T, Brianzoni E, Capoccetti F et al (2007) A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542–3546CrossRefPubMedGoogle Scholar